FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078641298> ?p ?o ?g. }

• W2078641298 endingPage "91" @default.
• W2078641298 startingPage "88" @default.
• W2078641298 abstract "Patients with diabetes mellitus have a variety of platelet and coagulation system dysfunctions. At least theoretically, these can contribute to microvascular complications. Intensive glycemic control has been demonstrated to decrease microvascular complications in type 1 diabetics. We studied 16 patients with type 1 diabetes mellitus (11 men and five women; mean age, 39 years) with albuminuria greater than 0.1 g/d and/or proteinuria greater than 0.3 g/d and a creatinine clearance rate higher than 30 mL/min. They received a regimen including three to four injection of insulin per day with or without a weekly infusion of intravenous insulin, and were evaluated for 6 months. We compared the plasma level of von Willebrand factor, platelet aggregation responses to adenosine diphosphate (ADP), epinephrine , and collagen, and platelet adhesion at the beginning of the study and at follow-up intervals. Glycemic control improved significantly. There were no significant differences in the platelet aggregation responses to ADP (1.59 ± 0.34 v 1.88 ± 0.23 mmol/L, P = .3; nomrla, 4.6 ± 0.2), epinephrine (0.50 ± 0.20 v 1.11 ± 0.31 mmol/L, P = .06; normal, 7.6 ± 1.5), or collagen (92.4 ± 6.61 v 82.60 ± 3.78 seconds, P = .6; normal, 79.1 ± 3.1) or in platelet adhesion (126.31 ± 16.95 v 195.08 ± 30.2 platelets, P = .34; normal, 68.6 ± 1.4). Baseline von Willebrand factor increased, but not significantly (166.38% ± 10.6% v 142.72% ± 14.73%, P = .21; normal, 102.0% ± 6.0%). In type 1 diabetic patients with established microvascular complications of nephropathy, a statistically significant improvement in glycemic control did not improve the in vitro platelet function abnormalities. Improved glycemic control delays the progression of microvascular disease through mechanisms not measured by tests of platelet function. Patients with diabetes mellitus have a variety of platelet and coagulation system dysfunctions. At least theoretically, these can contribute to microvascular complications. Intensive glycemic control has been demonstrated to decrease microvascular complications in type 1 diabetics. We studied 16 patients with type 1 diabetes mellitus (11 men and five women; mean age, 39 years) with albuminuria greater than 0.1 g/d and/or proteinuria greater than 0.3 g/d and a creatinine clearance rate higher than 30 mL/min. They received a regimen including three to four injection of insulin per day with or without a weekly infusion of intravenous insulin, and were evaluated for 6 months. We compared the plasma level of von Willebrand factor, platelet aggregation responses to adenosine diphosphate (ADP), epinephrine , and collagen, and platelet adhesion at the beginning of the study and at follow-up intervals. Glycemic control improved significantly. There were no significant differences in the platelet aggregation responses to ADP (1.59 ± 0.34 v 1.88 ± 0.23 mmol/L, P = .3; nomrla, 4.6 ± 0.2), epinephrine (0.50 ± 0.20 v 1.11 ± 0.31 mmol/L, P = .06; normal, 7.6 ± 1.5), or collagen (92.4 ± 6.61 v 82.60 ± 3.78 seconds, P = .6; normal, 79.1 ± 3.1) or in platelet adhesion (126.31 ± 16.95 v 195.08 ± 30.2 platelets, P = .34; normal, 68.6 ± 1.4). Baseline von Willebrand factor increased, but not significantly (166.38% ± 10.6% v 142.72% ± 14.73%, P = .21; normal, 102.0% ± 6.0%). In type 1 diabetic patients with established microvascular complications of nephropathy, a statistically significant improvement in glycemic control did not improve the in vitro platelet function abnormalities. Improved glycemic control delays the progression of microvascular disease through mechanisms not measured by tests of platelet function." @default.
• W2078641298 created "2016-06-24" @default.
• W2078641298 creator A5014110930 @default.
• W2078641298 creator A5039485202 @default.
• W2078641298 creator A5041758416 @default.
• W2078641298 creator A5056825572 @default.
• W2078641298 creator A5067110312 @default.
• W2078641298 creator A5075668584 @default.
• W2078641298 creator A5082304861 @default.
• W2078641298 creator A5089858920 @default.
• W2078641298 date "2000-01-01" @default.
• W2078641298 modified "2023-10-16" @default.
• W2078641298 title "Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease" @default.
• W2078641298 cites W1561751955 @default.
• W2078641298 cites W1966562996 @default.
• W2078641298 cites W1984380886 @default.
• W2078641298 cites W1986938454 @default.
• W2078641298 cites W1991942766 @default.
• W2078641298 cites W1992035079 @default.
• W2078641298 cites W2001563453 @default.
• W2078641298 cites W2007719564 @default.
• W2078641298 cites W2008552265 @default.
• W2078641298 cites W2008567943 @default.
• W2078641298 cites W2010726826 @default.
• W2078641298 cites W2012214760 @default.
• W2078641298 cites W2014420640 @default.
• W2078641298 cites W2016703545 @default.
• W2078641298 cites W2018196775 @default.
• W2078641298 cites W2023072129 @default.
• W2078641298 cites W2034902342 @default.
• W2078641298 cites W2043998212 @default.
• W2078641298 cites W2051322044 @default.
• W2078641298 cites W2055776235 @default.
• W2078641298 cites W2055880572 @default.
• W2078641298 cites W2058812862 @default.
• W2078641298 cites W2065645998 @default.
• W2078641298 cites W2084724086 @default.
• W2078641298 cites W2088763064 @default.
• W2078641298 cites W2090243052 @default.
• W2078641298 cites W2090720986 @default.
• W2078641298 cites W2093638740 @default.
• W2078641298 cites W2102360025 @default.
• W2078641298 cites W2112958044 @default.
• W2078641298 cites W2324517300 @default.
• W2078641298 cites W2337454357 @default.
• W2078641298 cites W2415496675 @default.
• W2078641298 cites W2417965667 @default.
• W2078641298 cites W2418070784 @default.
• W2078641298 cites W2769264260 @default.
• W2078641298 cites W3998058 @default.
• W2078641298 cites W405273222 @default.
• W2078641298 cites W4240916413 @default.
• W2078641298 cites W4244282174 @default.
• W2078641298 cites W4246231798 @default.
• W2078641298 doi "https://doi.org/10.1016/s0026-0495(00)90813-8" @default.
• W2078641298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10647069" @default.
• W2078641298 hasPublicationYear "2000" @default.
• W2078641298 type Work @default.
• W2078641298 sameAs 2078641298 @default.
• W2078641298 citedByCount "22" @default.
• W2078641298 countsByYear W20786412982012 @default.
• W2078641298 countsByYear W20786412982013 @default.
• W2078641298 countsByYear W20786412982017 @default.
• W2078641298 countsByYear W20786412982023 @default.
• W2078641298 crossrefType "journal-article" @default.
• W2078641298 hasAuthorship W2078641298A5014110930 @default.
• W2078641298 hasAuthorship W2078641298A5039485202 @default.
• W2078641298 hasAuthorship W2078641298A5041758416 @default.
• W2078641298 hasAuthorship W2078641298A5056825572 @default.
• W2078641298 hasAuthorship W2078641298A5067110312 @default.
• W2078641298 hasAuthorship W2078641298A5075668584 @default.
• W2078641298 hasAuthorship W2078641298A5082304861 @default.
• W2078641298 hasAuthorship W2078641298A5089858920 @default.
• W2078641298 hasConcept C126322002 @default.
• W2078641298 hasConcept C134018914 @default.
• W2078641298 hasConcept C2775859304 @default.
• W2078641298 hasConcept C2776174234 @default.
• W2078641298 hasConcept C2779306644 @default.
• W2078641298 hasConcept C2779394231 @default.
• W2078641298 hasConcept C2780009322 @default.
• W2078641298 hasConcept C2780473172 @default.
• W2078641298 hasConcept C2781232474 @default.
• W2078641298 hasConcept C2993802102 @default.
• W2078641298 hasConcept C555293320 @default.
• W2078641298 hasConcept C71924100 @default.
• W2078641298 hasConcept C89560881 @default.
• W2078641298 hasConceptScore W2078641298C126322002 @default.
• W2078641298 hasConceptScore W2078641298C134018914 @default.
• W2078641298 hasConceptScore W2078641298C2775859304 @default.
• W2078641298 hasConceptScore W2078641298C2776174234 @default.
• W2078641298 hasConceptScore W2078641298C2779306644 @default.
• W2078641298 hasConceptScore W2078641298C2779394231 @default.
• W2078641298 hasConceptScore W2078641298C2780009322 @default.
• W2078641298 hasConceptScore W2078641298C2780473172 @default.
• W2078641298 hasConceptScore W2078641298C2781232474 @default.
• W2078641298 hasConceptScore W2078641298C2993802102 @default.
• W2078641298 hasConceptScore W2078641298C555293320 @default.
• W2078641298 hasConceptScore W2078641298C71924100 @default.

• next